Cue Biopharma Revenue vs. Shares Owned By Institutions
| CUE Stock | USD 1.01 0.01 0.98% |
Total Revenue | First Reported 2015-12-31 | Previous Quarter 2.7 M | Current Value 3.3 M | Quarterly Volatility 1.6 M |
For Cue Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cue Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cue Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cue Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cue Biopharma over time as well as its relative position and ranking within its peers.
Cue |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.172 | Quarterly Revenue Growth 0.923 | Return On Assets (0.52) | Return On Equity (1.39) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cue Biopharma Shares Owned By Institutions vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cue Biopharma's current stock value. Our valuation model uses many indicators to compare Cue Biopharma value to that of its competitors to determine the firm's financial worth. Cue Biopharma is rated fifth in revenue category among its peers. It is rated below average in shares owned by institutions category among its peers . The ratio of Revenue to Shares Owned By Institutions for Cue Biopharma is about 232,726 . At present, Cue Biopharma's Total Revenue is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Cue Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Cue Revenue vs. Competition
Cue Biopharma is rated fifth in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 75.02 Million. Cue Biopharma holds roughly 5.49 Million in revenue claiming about 7% of equities under Health Care industry.
Cue Shares Owned By Institutions vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Cue Biopharma |
| = | 5.49 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Cue Biopharma |
| = | 23.59 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Cue Shares Owned By Institutions Comparison
Cue Biopharma is currently under evaluation in shares owned by institutions category among its peers.
Cue Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cue Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cue Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Cue Biopharma's change in net profit over the period of time. It can combine multiple indicators of Cue Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -110.3 K | -115.8 K | |
| Operating Income | -52.1 M | -54.8 M | |
| Net Loss | -50.7 M | -53.3 M | |
| Income Before Tax | -50.7 M | -53.3 M | |
| Total Other Income Expense Net | 1.4 M | 1.5 M | |
| Net Loss | -47.7 M | -50.1 M | |
| Net Loss | -50.7 M | -53.3 M | |
| Income Tax Expense | 3.3 M | 3.4 M | |
| Net Interest Income | 1.4 M | 1.5 M | |
| Interest Income | 2.7 M | 2.8 M | |
| Non Operating Income Net Other | 57.7 K | 91.8 K | |
| Change To Netincome | 10.9 M | 7.4 M | |
| Net Loss | (1.11) | (1.16) | |
| Income Quality | 0.79 | 0.61 | |
| Net Income Per E B T | 1.15 | 1.11 |
Cue Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cue Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cue Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cue Biopharma's important profitability drivers and their relationship over time.
Use Cue Biopharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cue Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cue Biopharma will appreciate offsetting losses from the drop in the long position's value.Cue Biopharma Pair Trading
Cue Biopharma Pair Trading Analysis
The ability to find closely correlated positions to Cue Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cue Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cue Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cue Biopharma to buy it.
The correlation of Cue Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cue Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cue Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cue Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Cue Biopharma position
In addition to having Cue Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Long Short Funds Thematic Idea Now
Long Short Funds
Funds or Etfs that are designed to hedge away market risk by investing in combination of bonds, stocks, derivative instruments as well as short positions to maximize returns irrespective of market conditions. The Long Short Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Long Short Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
To fully project Cue Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cue Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cue Biopharma's income statement, its balance sheet, and the statement of cash flows.